Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Aug 14, 2018

SELL
$35.15 - $51.45 $10.4 Million - $15.3 Million
-296,995 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$18.0 - $48.35 $5.35 Million - $14.4 Million
296,995 New
296,995 $11.6 Million

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $762M
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Point State Capital LP Portfolio

Follow Point State Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point State Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Point State Capital LP with notifications on news.